Jiangsu Recbio Advances with New Shingles Vaccine Trial

Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.

Jiangsu Recbio Technology Co., Ltd. has successfully completed the enrollment for the Phase III clinical trial of its new shingles vaccine, REC610. This vaccine, designed for adults over 40, is being tested for its efficacy and safety at multiple centers in China. With the market currently dominated by GlaxoSmithKline’s Shingrix, there is significant demand for a domestic alternative like REC610.

For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.